Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triciribine + carboplatin
- Development stage
- Unknown
- Lead developer
- Prescient Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Triciribine + carboplatin is an investigational combination of two small molecule oncology drugs. Triciribine (including its prodrug PTX-200) is an inhibitor of AKT phosphorylation and activation, suppressing the PI3K/AKT pathway, which is dysregulated in various cancers. Carboplatin is a DNA-damaging platinum-based chemotherapeutic that forms DNA crosslinks, leading to cell death and is widely used in ovarian and other cancers. The combination is being tested for synergistic antitumor activity and safety in ovarian cancer, particularly those with activated AKT signaling[2][4][5].
- Other names
- triciribine + carboplatinTCN + carboplatinPTX-200 + carboplatin
02
Targets
AKT2 (Rac-beta serine/threonine-protein kinase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)DNA
Beyond the preview
Go deeper on triciribine + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triciribine + carboplatin.